Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.72 USD
Change Today -0.0001 / -0.01%
Volume 383.5K
As of 4:15 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

cel-sci corp (CVM) Snapshot

Open
$0.72
Previous Close
$0.72
Day High
$0.74
Day Low
$0.71
52 Week High
07/1/14 - $1.30
52 Week Low
12/10/14 - $0.54
Market Cap
80.6M
Average Volume 10 Days
1.2M
EPS TTM
$-0.46
Shares Outstanding
111.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEL-SCI CORP (CVM)

Related News

No related news articles were found.

cel-sci corp (CVM) Related Businessweek News

No Related Businessweek News Found

cel-sci corp (CVM) Details

CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process, stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, provides peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

cel-sci corp (CVM) Top Compensated Officers

Chief Executive Officer, Treasurer and Direct...
Total Annual Compensation: $584.6K
Founder, Chairman and President
Total Annual Compensation: $393.3K
Senior Vice President of Operations and Corpo...
Total Annual Compensation: $247.9K
Senior Vice President of Research - Cellular ...
Total Annual Compensation: $213.2K
Senior Vice President of Regulatory Affairs
Total Annual Compensation: $197.4K
Compensation as of Fiscal Year 2014.

cel-sci corp (CVM) Key Developments

CEL-SCI Corporation Receives Authorization to Conduct its Phase 3 Multikine Trial in Spain

CEL-SCI Corporation announced that Spain’s Agency for Medicinal Products and Medicinal Devices has authorized the company to commence patient enrollment for its ongoing Phase 3 trial of its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection) in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer. Spain is the 22nd country to authorize CEL-SCI’s Phase 3 trial for patient enrollment. Multikine Phase 3 Study: the Multikine Phase 3 study is enrolling patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care (“SOC”) vs. subjects who are treated with SOC only. Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase 3 clinical trial as a potential first-line treatment for advanced primary squamous cell carcinoma of the head and neck. Multikine is designed to be a different type of therapy in the fight against cancer: one that appears to have the potential to work with the body’s natural immune system in the fight against tumors.

CEL-SCI Corporation Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended March 31, 2015

CEL-SCI Corporation reported unaudited earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported grant and other income of $197,620 compared to $67,157 a year ago. Operating loss was $7,759,343 compared to $6,226,435 a year ago. Net loss was $12,556,236 or $0.17 per diluted share compared to $13,365,580 or $0.24 per diluted share a year ago. The increase in net loss for the three and six month periods of 2015 as compared to the same periods in 2014 was primarily attributable to the increase in operating loss off-set by the reduced loss reported of the non-cash charge for the change in value of derivative instruments caused by a decrease in the Company’s common stock. For six months, the company reported grant and other income of $334,458 compared to $180,301 a year ago. Operating loss was $17,755,084 compared to $12,160,745 a year ago. Net loss available to common shareholders was of $20,401,554 or $0.27 per diluted share compared to $18,817,445 or $0.36 per diluted share a year ago. The rise in operating loss was attributable to an increase in research and development expenses of approximately $1,717,000 in the first half of fiscal year 2015 compared to the first half of fiscal year 2014.

CEL-SCI Corporation Reports Patient Enrollment in 2015 for its Phase III Head and Neck Cancer Trial

CEL-SCI Corporation announced that in April it enrolled 31 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection). The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only. Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. The trial is expected to expand into a total of approximately 100 clinical centers in about 25 countries. Multikine is also being tested in a Phase I study under a CRADA (Cooperative Research and Development Agreement) with the U.S. Naval Medical Center, San Diego as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women. CEL-SCI has entered into two co-development agreements with Ergomed to further the development of Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CVM:US $0.72 USD -0.0001

CVM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CVM.
View Industry Companies
 

Industry Analysis

CVM

Industry Average

Valuation CVM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 136.0x
Price/Book 200.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 155.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEL-SCI CORP, please visit www.cel-sci.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.